Stocktoria
Viridian Therapeutics, Inc.DE VRDN
Viridian Therapeutics, Inc.DE (VRDN) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $70.8M at a -483.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.916 |
| Retained earnings / assets | -1.488 |
| EBIT / assets | -0.404 |
| Equity / liabilities | 4.074 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.DE | 2/9 | 2.72 | — | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 3/9 | -1.34 | — | +153.5% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| BCYC | BICYCLE THERAPEUTICS PLC | 1/9 | 5.27 | — | +105.8% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
About Viridian Therapeutics, Inc.DE
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
FAQ
Is VRDN financially healthy?
Viridian Therapeutics, Inc.DE's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does VRDN pay a dividend?
No, Viridian Therapeutics, Inc.DE does not currently pay a dividend.
How profitable is VRDN?
In FY2025, Viridian Therapeutics, Inc.DE had a net margin of -483.6% and a return on equity of -47.4%.
What is the analyst price target for VRDN?
The average Wall-Street price target for Viridian Therapeutics, Inc.DE is $35.50, about 55.2% above the recent price, from 16 analysts (consensus: strong buy).
Is VRDN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Viridian Therapeutics, Inc.DE: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.